209 related articles for article (PubMed ID: 11895797)
1. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution.
Klangsinsirikul P; Carter GI; Byrne JL; Hale G; Russell NH
Blood; 2002 Apr; 99(7):2586-91. PubMed ID: 11895797
[TBL] [Abstract][Full Text] [Related]
2. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
Ratzinger G; Reagan JL; Heller G; Busam KJ; Young JW
Blood; 2003 Feb; 101(4):1422-9. PubMed ID: 12393688
[TBL] [Abstract][Full Text] [Related]
3. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
Hale G; Zhang MJ; Bunjes D; Prentice HG; Spence D; Horowitz MM; Barrett AJ; Waldmann H
Blood; 1998 Dec; 92(12):4581-90. PubMed ID: 9845524
[TBL] [Abstract][Full Text] [Related]
4. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
5. CAMPATH-1 antibodies in stem-cell transplantation.
Hale G; Cobbold S; Novitzky N; Bunjes D; Willemze R; Prentice HG; Milligan D; MacKinnon S; Waldmann H;
Cytotherapy; 2001; 3(3):145-64. PubMed ID: 12171722
[TBL] [Abstract][Full Text] [Related]
6. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
Simpson D
BioDrugs; 2003; 17(3):147-54. PubMed ID: 12749751
[TBL] [Abstract][Full Text] [Related]
7. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
Hale G; Waldmann H
Bone Marrow Transplant; 1994 May; 13(5):597-611. PubMed ID: 8054913
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of CAMPATH-1H in BMT patients.
Rebello P; Cwynarski K; Varughese M; Eades A; Apperley JF; Hale G
Cytotherapy; 2001; 3(4):261-7. PubMed ID: 12171714
[TBL] [Abstract][Full Text] [Related]
9. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
Cull GM; Haynes AP; Byrne JL; Carter GI; Miflin G; Rebello P; Hale G; Waldmann H; Russell NH
Br J Haematol; 2000 Mar; 108(4):754-60. PubMed ID: 10792280
[TBL] [Abstract][Full Text] [Related]
10. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
Williams RJ; Clarke E; Blair A; Evely R; Hale G; Waldmann H; Brookes S; Pamphilon DH
Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
[TBL] [Abstract][Full Text] [Related]
11. Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
Naparstek E; Delukina M; Or R; Nagler A; Kapelushnik J; Varadi G; Strauss N; Cividalli G; Aker M; Brautbar C; Waldmann H; Hale G; Slavin S
Exp Hematol; 1999 Jul; 27(7):1210-8. PubMed ID: 10390197
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
Chakrabarti S; Hale G; Waldmann H
Transplant Proc; 2004 Jun; 36(5):1225-7. PubMed ID: 15251298
[TBL] [Abstract][Full Text] [Related]
13. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics.
Khouri IF; Albitar M; Saliba RM; Ippoliti C; Ma YC; Keating MJ; Champlin RE
Bone Marrow Transplant; 2004 Apr; 33(8):833-7. PubMed ID: 14755312
[TBL] [Abstract][Full Text] [Related]
14. Campath-1G impairs human natural killer (NK) cell-mediated cytotoxicity.
Condiotti R; Nagler A
Bone Marrow Transplant; 1996 Oct; 18(4):713-20. PubMed ID: 8899185
[TBL] [Abstract][Full Text] [Related]
15. T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease.
Jacobs P; Wood L; Fullard L; Waldmann H; Hale G
Bone Marrow Transplant; 1994 Jun; 13(6):763-9. PubMed ID: 7920312
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab.
Buggins AG; Mufti GJ; Salisbury J; Codd J; Westwood N; Arno M; Fishlock K; Pagliuca A; Devereux S
Blood; 2002 Sep; 100(5):1715-20. PubMed ID: 12176892
[TBL] [Abstract][Full Text] [Related]
17. Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors.
Hamblin M; Marsh JC; Lawler M; McCann SR; Wickham N; Dunlop L; Ball S; Davies EG; Hale G; Waldmann H; Gordon-Smith EC
Bone Marrow Transplant; 1996 May; 17(5):819-24. PubMed ID: 8733704
[TBL] [Abstract][Full Text] [Related]
18. Fast appearance of donor dendritic cells in human skin: dynamics of skin and blood dendritic cells after allogeneic hematopoietic cell transplantation.
Auffermann-Gretzinger S; Eger L; Bornhäuser M; Schäkel K; Oelschlaegel U; Schaich M; Illmer T; Thiede C; Ehninger G
Transplantation; 2006 Mar; 81(6):866-73. PubMed ID: 16570010
[TBL] [Abstract][Full Text] [Related]
19. Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft.
Loeff FC; van Egmond EHM; Moes DJAR; Wijnands C; Von Dem Borne PA; Veelken H; Falkenburg JHF; Jedema I; Halkes CJM
Transpl Immunol; 2019 Dec; 57():101209. PubMed ID: 31207283
[TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity conditioning allogeneic stem cell transplantation with donor T-cell depletion using alemtuzumab added to the graft ('Campath in the bag').
von dem Borne PA; Starrenburg CW; Halkes SJ; Marijt WA; Fibbe WE; Falkenburg JH; Willemze R
Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S27-9. PubMed ID: 19561408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]